James O. Jones

3.9k total citations · 2 hit papers
18 papers, 3.0k citations indexed

About

James O. Jones is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, James O. Jones has authored 18 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in James O. Jones's work include Renal cell carcinoma treatment (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Renal and related cancers (5 papers). James O. Jones is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Renal and related cancers (5 papers). James O. Jones collaborates with scholars based in United Kingdom, United States and Germany. James O. Jones's co-authors include Douglas T. Fearon, Matthew Kraman, Edward W. Roberts, David A. Tuveson, Tobias Janowitz, Otávia L. Caballero, Qi Zhao, Sarah A. Teichmann, Andrew Deonarine and Christine Feig and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

James O. Jones

17 papers receiving 2.9k citations

Hit Papers

Targeting CXCL12 from FAP... 2010 2026 2015 2020 2013 2010 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer
    2013 1.5k citations Christine Feig, James O. Jones et al. Proceedings of the National Academy of Sciences profile →
  2. Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
    2010 918 citations Matthew Kraman, James N. Arnold et al. Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James O. Jones United Kingdom 9 2.3k 1.3k 842 552 240 18 3.0k
Matthew Kraman United Kingdom 14 2.5k 1.1× 1.5k 1.2× 1.1k 1.3× 588 1.1× 239 1.0× 21 3.5k
Brett L. Knolhoff United States 17 2.9k 1.3× 2.8k 2.1× 1.2k 1.4× 576 1.0× 258 1.1× 27 4.6k
Klara Balint United States 15 1.4k 0.6× 1.4k 1.1× 1.2k 1.4× 454 0.8× 226 0.9× 20 2.7k
Giacomo Desantis Italy 10 1.2k 0.5× 1.6k 1.2× 648 0.8× 540 1.0× 222 0.9× 13 2.5k
Ursina Teitelbaum United States 19 1.9k 0.8× 1.2k 0.9× 596 0.7× 452 0.8× 108 0.5× 54 2.7k
Timothy M. Nywening United States 10 1.8k 0.8× 1.5k 1.2× 555 0.7× 332 0.6× 153 0.6× 17 2.6k
Floriane Pelon France 7 1.7k 0.7× 861 0.6× 1.0k 1.2× 644 1.2× 202 0.8× 7 2.4k
Ajeeta B. Dash United States 11 1.8k 0.8× 523 0.4× 1.6k 1.9× 808 1.5× 174 0.7× 23 3.6k
Laetitia Fuhrmann France 19 1.3k 0.6× 577 0.4× 1.0k 1.2× 704 1.3× 166 0.7× 29 2.3k
Ferdinando Pucci United States 17 1.2k 0.5× 1.7k 1.3× 1.5k 1.8× 738 1.3× 162 0.7× 25 3.1k

Countries citing papers authored by James O. Jones

Since Specialization
Citations

This map shows the geographic impact of James O. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James O. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James O. Jones more than expected).

Fields of papers citing papers by James O. Jones

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James O. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James O. Jones. The network helps show where James O. Jones may publish in the future.

Co-authorship network of co-authors of James O. Jones

This figure shows the co-authorship network connecting the top 25 collaborators of James O. Jones. A scholar is included among the top collaborators of James O. Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James O. Jones. James O. Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Wray, Richard, Ferdia A. Gallagher, Iosif Mendichovszky, et al.. (2025). Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus. Nature Communications. 16(1). 3870–3870. 1 indexed citations
2.
3.
Priest, Andrew N., Andrew B. Gill, Iosif Mendichovszky, et al.. (2024). High-resolution and highly accelerated MRI T2 mapping as a tool to characterise renal tumour subtypes and grades. European Radiology Experimental. 8(1). 76–76. 1 indexed citations
4.
5.
Jones, James O., Anne Y. Warren, Helen Mossop, et al.. (2024). 75 WIRE: Window of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in Renal Cell Cancer. The Oncologist. 29(Supplement_1). S15–S16. 1 indexed citations
6.
Welsh, Sarah J., Emmette R. Hutchison, John A. D. Aston, et al.. (2023). Common methodological pitfalls in ICI pneumonitis risk prediction studies. Frontiers in Immunology. 14. 1228812–1228812. 1 indexed citations
7.
Vemulkar, Tarun, James O. Jones, Andrew P. Stewart, et al.. (2023). Lithographically defined encoded magnetic heterostructures for the targeted screening of kidney cancer. Nanoscale Advances. 6(1). 276–286. 1 indexed citations
8.
Jones, James O., Will Ince, Sarah J. Welsh, & Grant D. Stewart. (2022). Activity of Immunotherapy Regimens on Primary Renal Tumours: A Systematic Review. Apollo (University of Cambridge). 6(4). 221–236. 3 indexed citations
9.
Jones, James O., et al.. (2022). Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st‐line BRAF‐targeted therapy. Pigment Cell & Melanoma Research. 35(6). 595–604. 3 indexed citations
10.
Munir, Hafsa, James O. Jones, Tobias Janowitz, et al.. (2021). Stromal-driven and Amyloid β-dependent induction of neutrophil extracellular traps modulates tumor growth. Nature Communications. 12(1). 683–683. 129 indexed citations
11.
Jones, James O., et al.. (2020). Microenvironmental modulation of the developing tumour: an immune‐stromal dialogue. Molecular Oncology. 15(10). 2600–2633. 12 indexed citations
12.
Jones, James O. & Elizabeth Smyth. (2019). Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes. Cancer Treatment Reviews. 84. 101950–101950. 20 indexed citations
13.
Flint, Thomas R., James O. Jones, Miriam Ferrer, Francesco Colucci, & Tobias Janowitz. (2018). A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy. Seminars in Oncology. 45(3). 170–175. 16 indexed citations
14.
Przanowski, Piotr, Justin S. A. Perry, James O. Jones, et al.. (2018). A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer. Cancer Cell. 34(2). 331–345.e11. 30 indexed citations
15.
Jones, James O., et al.. (2013). TOX3 Mutations in Breast Cancer. PLoS ONE. 8(9). e74102–e74102. 22 indexed citations
16.
Roberts, Edward W., Andrew Deonarine, James O. Jones, et al.. (2013). Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. The Journal of Experimental Medicine. 210(6). 1137–1151. 300 indexed citations
17.
Feig, Christine, James O. Jones, Matthew Kraman, et al.. (2013). Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer. Proceedings of the National Academy of Sciences. 110(50). 20212–20217. 1490 indexed citations breakdown →
18.
Kraman, Matthew, James N. Arnold, Edward W. Roberts, et al.. (2010). Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α. Science. 330(6005). 827–830. 918 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthew Kraman Breakdown of academic impact, for papers by Brett L. Knolhoff Breakdown of academic impact, for papers by Klara Balint Breakdown of academic impact, for papers by Giacomo Desantis Breakdown of academic impact, for papers by Ursina Teitelbaum Breakdown of academic impact, for papers by Timothy M. Nywening Breakdown of academic impact, for papers by Floriane Pelon Breakdown of academic impact, for papers by Ajeeta B. Dash Breakdown of academic impact, for papers by Laetitia Fuhrmann Breakdown of academic impact, for papers by Ferdinando Pucci
Rankless by CCL
2026